PC | Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma https://t.co/9ARIMH3RRi
145 followers
2,454 followers
Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma #lymphoma #lymsm https://t.co/aiP3NjyhPZ
2,454 followers
Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma #lymphoma #lymsm https://t.co/yPnAhnMcSn
32,876 followers
New Research: Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma: Polatuzumab vedotin, marketed under the trade name POLIVY®, is a CD79b-targeted antibody-drug… https://t.co/2xO